* Nektar Therapeutics reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of seven analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -26 cents to -16 cents per share.

* Revenue fell 0.1% to $24.12 million from a year ago; analysts expected $18.28 million.

* Nektar Therapeutics's reported EPS for the quarter was a loss of 18 cents​.

* The company reported a quarterly loss of $37.06 million.

* Nektar Therapeutics shares had risen by 6.9% this quarter and gained 146.0% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 3.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Nektar Therapeutics is 4.00 This summary was machine generated from LSEG data November 8 at 04:38 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.21 -0.18 Beat

Jun. 30 2024 -0.20 -0.25 Missed

Mar. 31 2024 -0.19 -0.19 Met

Dec. 31 2023 -0.21 -0.22 Missed